Company intelligence / Profile preview
Opus Pharmaceuticals
Sandton, Gauteng, South Africaopuspharma.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Opus Pharmaceuticals is a South African, family-owned pharmaceutical company established in 1990. The company appears to focus primarily on marketed gastrointestinal products, with Kantrexil tablets and suspension positioned as its flagship prescription brand for the treatment of specific and non-specific gastroenteritis. Publicly available information suggests Opus is a commercial-stage specialty pharma business rather than a clinical-development biotech, with limited evidence of a broader R&D pipeline. Its business profile centers on branded pharmaceutical products and patient information services in South Africa, particularly in gut health.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Opus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opus Pharmaceuticals.